Gates Injects UK-US Dementia Discovery Fund With $50m And Fresh Purpose
The Dementia Discovery Fund won a $50m private investment from Bill Gates – plus his ringing support to probe beyond the amyloid beta hypothesis in hopes of eventually defeating Alzheimer's.
You may also be interested in...
Biomarkers will be key to winning the race to a successful AD drug. Even then, drugmakers must build the infrastructure for getting therapy to the right patients at the right time.
Five funds raised more than $1bn to back biotech firms; Arcus leads recent VC rounds with $107m GV-backed Series C; Celgene, Valeant sell notes to retire debt; and Alnylam cashes in on investor goodwill.
The UK-based Dementia Discovery Fund's first investment was a bit of let-down for academic scientists as it went to an established US biotech company. But this could all change with the appointment of chief scientific officer Dr Tetsuyuki Maruyama (formerly Paul Chapman), who will start his new job in April. Despite a strong pharma executive background, his origins as an academic neuroscientist ensure he knows exactly what is being expected of him by the academic masses.